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Abstract
Purpose Patient-reported data are playing an increasing
role in health care. In oncology, data from quality of life
(QoL) assessment tools may be particularly important for
those with limited survival prospects, where treatments aim
to prolong survival while maintaining or improving QoL.
This paper examines the use and impact of using QoL
measures on health care of cancer patients within a clinical
setting, particularly those with brain cancer. It also exam-
ines facilitators and challenges, and provides implications
for policy and practice.
Design We conducted a systematic literature review, 15
expert interviews and a consultation at an international
summit.
Results The systematic review found no relevant inter-
vention studies specifically in brain cancer patients, and
after expanding our search to include other cancers, 15
relevant studies were identified. The evidence on the
effectiveness of using QoL tools was inconsistent for
patient management, but somewhat more consistent in
favour of improving patient–physician communication.
Interviews identified unharnessed potential and growing
interest in QoL tool use and associated challenges to
address.
Conclusion Our findings suggest that the use of QoL
tools in cancer patients may improve patient–physician
communication and have the potential to improve care, but
the tools are not currently widely used in clinical practice
(in brain cancer nor some other cancer contexts) although
they are in clinical trials. There is a need for further
research and stakeholder engagement on how QoL tools
can achieve most impact across cancer and patient con-
texts. There is also a need for policy, health professional,
research and patient communities to strengthen information
exchange and debate, support awareness raising and pro-
vide training on tool design, use and interpretation.
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Introduction
In many brain cancer patients, current treatment options are
not curative, focussing instead on prolonging survival
while maintaining or improving patients’ quality of life
(QoL) [1, 2]. There is often a need to balance the benefits
of extended survival or delayed progression with the
potential negative effects of treatment on QoL [3]. As new
and more targeted treatments are developed, with increased
risk of severe side effects and neurotoxicity, the importance
of considering QoL as an outcome increases even further
[4].
QoL, in this patient group, is measured using a wide
range of instruments/tools [1, 2, 5]. Tools available range
from those which measure generic quality of life aspects
(e.g. the SF 36 and the Nottingham Health Profile) to
cancer-specific tools and brain cancer-/tumour-specific
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questionnaires within these. Some tools focus on many
aspects of QoL, while others focus on specific functions or
symptoms. For example, the Karnofsky performance status
scale focuses on functional performance while EORTC and
FACT-br tools cover various physical, role, emotional,
cognitive and social functioning and diverse symptoms.
Tools are often modular, incorporating a general (core)
questionnaire, for use with all cancer patient groups, sup-
plemented by a brain cancer-/tumour-specific questionnaire
(module), which focuses on issues of particular relevance
to this patient group. For an overview of tools, see Table S1
in the supplementary files.
The use of these tools in the measurement of QoL as an
outcome in clinical trials has become increasingly impor-
tant, in addition to survival [1, 2, 5–11]. As well as using
QoL in clinical trials, a number of authors have also
hypothesised that QOL data could support more inclusive
clinical decision-making on care regimes and management,
by providing patients’ perspectives on their care [5, 12].
However, there is a lack of knowledge on how the use of
QoL instruments could lead to changes in clinical decision-
making and patient management [5, 13, 14].
We undertook a systematic review to examine the
impact of using QoL tools on the health care of brain
cancer patients in clinical settings. In addition, we under-
took key informant interviews and stakeholder consulta-
tions in order to explore why tools are, or are not, used in
care contexts, and enablers and barriers to their use. Based
on this evidence, we suggest potential implications for
future policy and oncology practice.
Design
Systematic review
The systematic review was conducted according to pub-
lished guidance for systematic reviews of health interven-
tions [15] and is reported in line with PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-analy-
ses) guidelines [16].
Any type of study that evaluated the use of a QoL tool as
an intervention in routine clinical practice, and/or used
QoL data in order to make a change in patient care, was
eligible for inclusion. Initially, participants of interest were
restricted to patients with brain cancer. However, we found
no relevant studies exclusively in this patient group. Given
the paucity of this literature, we expanded the search to
consider all relevant interventions within all oncology
settings, except a surgical oncological setting,1 with a view
to identifying potentially transferable insights to inform a
future research agenda.
Primary outcomes of interest related to change in care
management. They included, but were not limited to,
patient–physician communication, patient treatment
adherence or clinical decision-making/clinical manage-
ment/changes in treatment pathways. Studies that only
examined the feasibility, validity, reliability or accept-
ability of QoL tools were not included. Studies that
examined QoL for predictive purposes, such as survival,2
were also not included. The search strategy, study selec-
tion, data extraction and risk of bias assessment methods
are presented in Table 1.
Studies were summarised in a narrative synthesis.
Where data allowed, we computed study-level standardised
mean differences (SMD) between comparison groups with
95 % confidence intervals. Visual presentation of these
results is presented in forest plots. Due to clinical hetero-
geneity between the studies, meta-analyses were not
conducted.
Key informant interviews
To complement and expand on the evidence from the
systematic review, we conducted telephone interviews with
professionals on quality of life and/or brain cancer and
advocacy group representatives from European and North
American countries, as well as pan-European organisa-
tions. We interviewed individuals who had experience
implementing and/or conducting research on QoL tools in
patients with brain cancer, many of whom could also
comment on what QoL tools are used across various types
of cancers. Interviewees were identified through a combi-
nation of publication research and a snow-balling
approach. They were invited by email, with an explanation
of the background to the study. Interviews were conducted
by a single researcher (SM, SP, EH, CML, JE) following a
semi-structured format and lasted 30–60 min. With con-
sent, interviews were audio-recorded and transcribed.
Interview data were coded by a single researcher (SP) and
checked by a second researcher (SM), guided by initial
interview themes. Additional themes were added as they
emerged from the data. The interviews were rooted in an
approach combining questions exploring particular themes
(but not driven by any positivist hypotheses on the themes)
and also allowing for emerging issues to be captured, coded
and grouped into analytical constructs—thus, the analysis
1 Studies that evaluated a QoL tool to make surgical decisions was
beyond the remit of this review; we were primarily interested in
Footnote 1 continued
general clinical care, and surgery is not always an option for terminal
brain cancer patients.
2 Studies that used QoL tools as a predictive tool were not included,
as the majority of these types of studies report outcomes that are
indirectly applicable to our research question.
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followed principles rooted in grounded theory [20]. In
total, we conducted 15 interviews between July and
October 2015. The professional and sector background of
those interviewed, as well as country background, is rep-
resented in Fig. 1 Profiles of interviewees broken down by
sector, country and profession.
Stakeholder consultation at the IBTA summit
We undertook a stakeholder consultation at the Interna-
tional Brain Tumour Alliance (IBTA) Second World
Summit of Brain Tumour Patient Advocates (October
2015). We consulted representatives on issues explored in
the interviews, during plenary and parallel sessions, and
discussed our emerging findings. The majority of partici-
pants were from patient advocacy groups, patient support
groups and research funding groups; academics, clinicians
and industry representatives were also present. We also
received written feedback from 19 representatives. Data
were coded and triangulated against insights from the
interview data.
Results
The impact of QoL assessment tools in routine
practice in oncology settings
The systematic review identified 15 studies (reported in 19
articles) on the use of QoL assessment tools in clinical
cancer care settings.3 Three of the studies were considered
to have a low risk of bias [21–24], with the remaining
studies having either an ‘‘unclear’’ or ‘‘high risk’’ of bias
(see supplementary table S3). Figure 2 illustrates the flow
of studies through the systematic review process.
Of the 13 studies conducted in adults, different cancer
patient groups were represented including those with lung
cancer [23, 25, 26], prostate and/or breast cancer [22, 27,
28] or various types of cancers [21, 29–34], including head
cancer [29]. The two studies conducted in children and
teens included various types of cancers, including brain
tumours [24, 35].
Nine of the studies examined the effectiveness of the
European Organisation for Research and Treatment of
Cancer QoL Questionnaire C30 (EORTC QLQ-30) ques-
tionnaire. The remaining six studies variously examined
the Functional Assessment of Cancer Therapy—General
(FACT-G), Prostate QOL (PROSQoLI), QoL in Childhood
Oncology (QLIC-ON PROfile), Pediatric QoL and Evalu-
ation of Symptom Technology (PediQUEST), Electronic
Self-report Assessment-Cancer (ESRA-C) and the Patient-
Reported Outcomes Measurement Information System
(PROMIS). Four types of outcomes dominated the litera-
ture, which are presented below. Details of the character-
istics of the included studies and their results are presented
in Table S3 (Supplementary files).
Table 1 Systematic review search strategy, study selection, data extraction and risk of bias assessment
Search strategy Electronic searches of four research literature databases (PubMed, EMBASE, Cochrane (SR & Trials), Web of
Science (SCI)) were conducted from 2000 up to 15 July 2015. In addition, searches for grey literature were
conducted in OAIster, OpenGrey, NYAM Grey Literature Report and Lexis Nexis, up to 11 September 2015.
Details of the electronic searches are provided in supplementary resource S2. Searches of eligible studies’
reference lists and forward citation tracking (using Google Scholar and PubMed) were also conducted. Initially,
no language or date restrictions were applied, but due the large number of references identified, the search was
restricted to English language publications and to full publications (i.e. not conference abstracts)
Study selection and data
extraction
Retrieved title–abstract records were initially screened by one of several reviewers (SK, JE, SB, TB-G or EH)
against the PICOS criteria. A random sample of 10 % of records was independently screened by a second
reviewer. Full-text screening of potentially eligible study reports was undertaken by at least two reviewers
working independently, with any discrepancies resolved by a third reviewer. Study data were extracted by one
reviewer and checked by a second reviewer
Risk of bias assessment Risk of bias assessments were done by one reviewer and checked by a second reviewer. For the RCTs, the
Cochrane Risk of Bias tool [15] was used to assess potential bias in studies for each outcome; six criteria were
considered: random sequence generation, allocation concealment, blinding of participants, personnel (where
feasible) and outcome assessors, baseline comparability between groups, incomplete outcome data, and selective
outcome reporting. Risk of bias judgements in domains judged most critical (sequence generation, allocation
concealment, incomplete outcome data) was used to determine a summary study-level risk of bias. For cohort
studies, and pre–post studies, we used criteria published on websites [17, 18]. Lastly, we used GRADE criteria
[19] to enable assessment of the quality of the body of evidence for each outcome
3 Given the paucity of literature for the brain patient group, we
expanded the search to consider all relevant interventions within all
oncology settings, with a view to identifying potentially transferable
insights to inform future studies.
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Physician (or nurse)–patient communication
Ten studies4 assessed this outcome [21, 23, 25, 27–30, 33–
35]. Four studies examined the frequency with which QoL
was discussed, with consistency shown in favour of using a
QoL tool to improve communication (Fig. 3). Eight studies
examined more specific QoL issues; the issues assessed,
and the results, were inconsistent across studies. Those
found to be significantly more frequently discussed during
consultation in the intervention groups compared with the
control groups include social functioning, fatigue and
dyspnoea [30], emotional functioning [23, 29, 33, 35],
psychosocial functioning [35] and daily activities [33].
Fig. 1 Profiles of interviewees broken down by sector, country and profession
Records identified through 





















n Additional records identified through other sources 
(n = 9 – grey literature 
and n = 8 – reference lists/forward searching )
Total records screened
(n = 18,483) 
Records excluded
(n = 18,420)
Full-text articles assessed for 
eligibility (n = 63)
Full-text articles excluded, 
with reasons (n = 44)
Studies included in the review 
(n = 15, published, in 19 papers)
Fig. 2 PRISMA flow diagram of the flow of citations reviewed during the systematic review
4 Five RCTs, two cohorts, two longitudinal studies and one before-
and-after study.
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Patient management
Twelve studies5 reported on outcomes related to patient
management [21–24, 26–28, 30, 32–35]. Four reported on
the number of actions/medical decisions taken during
consultations, none of which found significant effects
(Fig. 4). An additional study reported that the proportion of
patients who received at least one therapeutic option for
QoL therapy did not differ between the intervention and
control groups [22].
Three studies examined the number of medical actions
taken for different types of QoL domains/issues (such as
emotional concerns) during consultations, but very few
significant effects were observed (Table 2). Four studies
reported on specific actions taken during consultations. In
these studies, no significant effects were observed between
intervention and control groups in the frequency of medi-
cation prescription, referrals, test ordering or modification/
cessation of chemotherapy, and inconsistent effects were
observed for counselling (Table 2).
In addition to these two main outcomes, secondary
outcome measures reported included the impact of the use
of QoL tools as part of the consultation process on patient
well-being and on patient satisfaction with their care/
treatment. Overall, there was evidence to suggest that the
use of tools had no, or a very small, effect on either patient
QoL or patient satisfaction.
In the rest of the paper, we draw on interview findings to
explore the current use of QoL tools in healthcare contexts
with a particular emphasis on brain cancer, enablers and
barriers to their use and implications for the future. This
evidence is supplemented with insights from stakeholder
consultation at the IBTA summit and jointly expands on
and complements the findings from the systematic review.
The primarily focus was on the brain cancer context, but
also—in line with an inductive approach—revealed some
wider reaching insights of relevance across different types
of cancers. The aim of the interviews was to scope a
diverse range of issues that could inform further studies. In
line with this, and especially considering the scarcity of
studies on the use of QoL tools as an intervention in cancer
care, we did not aim to quantify the strength of different
responses in this aspect of the study, but rather to capture
the diversity of issues perceived to be important and
relevant.
Current use of QoL assessment tools in healthcare
delivery for cancer patients, with particular
emphasis on brain cancer
Although interview evidence identified some cases of the
use of QoL tools in the treatment and care of patients with
brain cancer (see Box 1),6 their use in clinical contexts is
reportedly rare, both for brain cancer and wider cancer
care. Where QoL tools are used, this was cited to be on the
initiative of a key individual. Overall interviewees noted
that QoL tools are principally used within clinical trials,
and many of the tools used in the care of brain cancer
patients differ to the tools used in clinical trials (a matter
we return to later in the paper). However, interviewees
pointed to opportunities for ‘‘spillover effects’’ from the
use of QoL assessment tools in the care of patients par-
ticipating in trials to other patients in the same clinical
setting.7
Despite the reported low levels of routine use at present,
there was broad consensus among interviewees that QoL
tools have unharnessed potential to ‘‘improve daily care’’.8
This was perceived to be exemplified by the fact that both
the International Society for Quality of Life Research and
the International Society for Pharmacoeconomics and
Outcomes Research are investigating the use in the clinical
practice setting.9 The principal benefits reported by inter-
viewees related to diverse aspects of improved patient–
physician communication in both brain cancer and wider
Fig. 3 Studies that evaluated the frequency of QoL issues discussed during consultation
5 Five RCTs, four cohort studies, two longitudinal studies and one
before-and-after study.
6 There was a debate among the community of academics, healthcare
professionals, industry and policy authorities as to what is considered
an official QoL assessment tool and what are more informal
instruments. The Box highlights the instruments interviewees iden-
tified as using in clinical practice.
7 INT02, INT08.
8 11 interviewees: INT01, INT02, INT04, INT05, INT06, INT08,
INT09, INT10, INT11, INT13, INT14.
9 INT11.
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cancer care contexts. For example, interviewees considered
that QoL outcomes provide clinicians with a better
understanding of patients’ perspective,10,11 encouraging
discussions that enable clinicians to take a more holistic
view of patients’ needs.12 For patient advocacy group
representatives consulted, their particularly interest in QoL
tools related to their potential to help healthcare profes-
sionals understand patient needs, across cancer contexts.
‘‘QoL is an important outcome as it tells you how the
patient feels and we know there is a difference
between clinical parameters and subjective patient
parameters. Someone can be terribly sick but may not
feel it that way and vice versa. QoL is about the
patient perspective and the functioning of the patient
in his or her entirety’’.13
Interviewees also suggested that QoL tools could help
empower patients to play a more informed role in decision-
making through a greater understanding of the implications
of particular treatment on their QoL. This was considered
to be particularly pertinent to brain cancer care, given that
treatment is not curative.14,15
‘‘There is a particular concern with QoL in the brain
tumour field because there are no cures for many of
the diseases covered. Where there is no cure, the
priority is to minimise harm done to the patient by
treatments’’.16
In addition to patient–physician communication,17
interviewees identified additional potential uses including
using the tools to help assess the effects of environmental
changes in the clinic,18 or to help inform the most appro-
priate ways of delivering and communicating results of
scans19 to patients. During stakeholder consultation wider
uses of QoL were noted, including their use as an advocacy
tool in discussions about valuing brain cancer treatments
with regulators, which highlights the need for more
effective communication of findings from clinical trials to
decision-makers.20 For example, it was highlighted that
QoL results from trials were often not at the forefront of
Fig. 4 Studies that evaluated the numbers of actions/medical decisions taken during consultation
Table 2 Number of medical actions taken and actions taken for specific domains/issues as identified in the systematic review
Outcome Overview of results
Number of actions taken for specific domains/
issues (n = 3 studies)
Of two studies that reported on the number of actions taken for specific domains, only
Nicklasson et al. [23] reported that the number of diagnostic and therapeutic interventions
directed to emotional concerns (SMD 0.45 [95 % CI 0.15–0.76]) and social concerns (SMD
0.38 [95 % CI 0.08–0.69]) were larger in the intervention group compared to the control
group. In addition, a study by Wolfe et al. [24] reported that the QoL intervention led to the
initiation of a psychosocial (56 %), pain (34 %), social work (33 %) or palliative care (29 %),
consult, but more detailed data were not reported
Number of specific actions (n = 4 studies) No studies reported differences between intervention and control groups for prescription of
medications [21, 30], ordering of tests [21, 30], referrals [21, 35] or modification/cessation of
chemotherapy [21]. Of three studies that evaluated advice/counselling as an outcome [21, 22,
30], only Detmar et al. [30] found that a statistically greater percentage of patients in the
intervention group received counselling from their physician on how to manage their health






15 INT04, INT07, INT08, INT11, INT14.
16 INT14.
17 INT01, INT03, INT11.
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trial findings, suggesting scope for more user-friendly
means of communication.
Factors influencing the use of QoL assessment tools
in cancer care, with a particular emphasis on brain
cancer
A range of facilitators and challenges associated with the
use of QoL tools were discussed by interviewees. These
span system-level, tool-, administration- and data-related
factors (Table 4). While some factors apply across all
cancers, others are disease or patient profile specific. For
example, a particular issue affecting the measurement of
QoL in brain cancer patients is the impact of neurocogni-
tive decline on the patients’ ability to complete question-
naires. Instead QoL questionnaires may have to be
completed or supported by a proxy. This was considered to
have implications for the value of the data produced.21 A
proxy may have a different interpretation of the patient’s
QoL, or a patient may respond differently compared to
when alone.22 Both situations could lead to bias.23 Another
feature of neurocognitive decline is that patients may not
be aware they are experiencing it and therefore may not be
able to report it on a QoL questionnaire.24
Other drivers of use are more universal. There was
perceived to still be a low level of awareness of the utility
of QoL tools among clinicians in oncology settings.
Although this awareness has somewhat increased, in part
facilitated by the inclusion of QoL sessions at conferences
and greater acceptance of QoL-related research in aca-
demic journals,25 there is scope for more awareness raising.
A number of interviewees pointed out that although clinical
trial protocols generally require that the impact of a treat-
ment on patients’ QoL be reported alongside clinical out-
comes, it is predominantly still considered a secondary
outcome.26,27 As such, interviewees reflected that QoL data
are sometimes published in lower impact journals and at a
later point in time, which reduces its visibility.
Interviewees also raised issues related to the adminis-
tration and interpretation of QoL data. This included a lack
of time to administer the measures, as well as time to
interpret the results and discuss with patients. Two inter-
viewees suggested that having individuals devoted to
administering QoL could help to overcome this challenge,
but that it also requires training for clinicians to be able to
understand QoL data, which is generally presented as a
series of numerical scores, and to be able to interpret what
this means for the particular patient. Current training was
considered to be insufficient.
‘‘Training is particularly important, as it is difficult to
interpret patients’ responses – clinicians are used to
looking at physical symptoms and find it challenging
to adapt to incorporating patients’ assessment of their
symptoms into their decision-making’’.28
The subjective nature of QoL assessment also affects ease
of interpretation, as different patients will differ in their
expectations of QoL and expectations may also alter as the
disease progresses, so tools may not remain equally
applicable across disease stages.29
The number of tools available also poses both oppor-
tunities for patient-centred and bespoke instruments, but
also some challenges. It was apparent from interviews that
there is no ‘‘gold standard’’ and interviewees discussed a
range of tools used (Table 3), with notable differences in
opinions between interviewees as to what constitutes an
official QoL assessment tool and what are more informal
instruments.30 In general, there was consensus across
interviews that in brain cancer care contexts general QoL
tools are used more often than cancer-specific tools, with
latter being used more frequently in clinical trials. In
clinical trials, it was perceived that the infrastructure and
resource capacity to administer and interpret more detailed
cancer-specific tools are better established which may help
explain the greater recourse to cancer-specific QoL ques-
tionnaires in trial contexts. One interviewee suggested that
general tools are more practical in oncology care settings as
they can be used across cancers, and more familiar to
healthcare staff, a view supported during the stakeholder
consultation. Two interviewees, however, raised concerns
about the utility of non-disease specific measures in pro-
viding insights on the distinct needs and concerns of a
particular patient segment.31
21 INT02, INT08, INT09, INT10, INT13.
22 For example, an interviewee reported that patients may report
more positively in the presence of a family member/loved one, in an








30 For example, one interviewee saw EQ-5D to be too general to
actually measure QoL, while another found it useful for circum-
stances where patients are unable to fill in a longer questionnaire; the
Psychological Screen for Cancer was also described as ‘‘not a real
QoL measure’’.
31 INT04, INT09.
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Discussion and conclusions
In our systematic review, we examined the impact of QoL
assessment tools in clinical cancer care settings, but did not
find any studies exclusively in brain cancer patients. Based
on published studies that included various other types of
cancer patients, there is some evidence to suggest that QoL
data may improve patient–physician communication, and
that emotional functioning in particular may be discussed
more frequently during consultation after implementation
of a QoL tool. Our finding is consistent with the wider
literature [1, 5, 10], which suggests that QoL tools enable
both doctors and patients to discuss more sensitive issues
and/or focus discussions on non-medical issues identified
as important by the patient [29, 36]. It is likely that these
findings are applicable to brain cancer patients, although
this merits further research.
It is not clear, however, whether the systematic review
evidence regarding the number of actions/medical deci-
sions, or QoL as an outcome, is applicable to brain cancer
patients specifically. Whereas the systematic review iden-
tified insights which may be transferable to brain cancer
contexts, this calls for further research, and particularly
given the notable gaps in the current literature on brain
cancer on this topic.
However, insights from our interviews and wider con-
sultation identified a diverse range of factors influencing
the use of QoL instruments in brain cancer care and cancer
care more widely, as overviewed in Table 4. As such, these
insights contribute to addressing the scarcity of evidence in
the literature. They also point to key areas for policy
consideration to do with communication and information
exchange, capacity building and regulation.
There was widespread belief among consulted experts
that QoL assessment tools have a beneficial role to play in
improving clinical practice through more inclusive
decision-making, despite a range of challenges that are yet
to be addressed. Many of these were seen to apply across
cancer contexts, but some were seen to be more brain
cancer specific. For example, given that some brain cancer
patients’ treatment is not curative, interviewees suggested
that brain cancer patients and their physicians might place
more importance on QoL when making decisions, than
those patients who have better survival prospects. Findings
from the systematic review might therefore underestimate
the impact of QoL on medical actions taken in this par-
ticular group of patients.
Factors related to time constraints to the use of tools32
and a need for establishing guidelines on tool use and
interpretation33 were seen to apply more widely across
cancer contexts and shed light on some capacity-building
priorities for future practice. Interviewees also suggested
that clinicians struggle to interpret QoL data and that
there are risks with QoL tools identifying issues beyond
the physicians’ perceived duty of care and/or control—as
a result, physicians may feel powerless to act on the data
[28, 29, 37]. This suggests that there is a need for
training on efficient and effective tool use, and for
information exchange between healthcare professionals
[28, 34, 38, 39], patient groups and wider stakeholders,
on experiences of good practice. This includes continu-
ing the debate on the benefits and limitations of different
tools, how to use them and adapt them, how to interpret
the data and how to empower patients’ to engage with
QoL tools and discussions so that they can make the
most informed treatment decision based on their own
needs.
Table 3 QoL tools with
potential applicability to a brain
cancer care context mentioned
by interviewees
Category QoL tool name




M.D. Anderson Symptom Inventory-Brain Tumor Module
Cancer specific Distress thermometer
Macmillan holistic needs assessment
Distress Assessment & Response Tool (DART)
Psychological Screen for Cancer (PSCAN)
General EQ-5D
SF-36
Karnofsky Performance Status scale
Barthel Index
32 INT01, INT02, INT04, INT06, INT07, INT08, INT11, INT12,
INT14.
33 INT05, INT15.
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Closely related to these issues are challenges to
managing a requisite degree of tool standardisation for
clinical trial purposes, with scope for customisation in care
to ensure patient-centred instruments [13, 14, 40]. A future
research agenda might explore further evaluations of
modular tools tailored to specific diseases, cultural contexts
and patient profiles (e.g. paediatrics, end-of-life care).
There is also a need to better understand how QoL
assessment tools can be used effectively across multidis-
ciplinary healthcare teams.
Finally, a need for more effective, user-friendly and
consistent ways of communicating QoL findings from
clinical trials to regulators and to clinicians was also
highlighted in our consultations as an area for considera-
tion in oncology policy. This was partly seen to relate to
the fact that QoL outcomes are considered secondary out-
come measures in clinical trials, often driven by funding
body requirements rather than an academic or clinician
interest.34 Such issues have been discussed in contexts
outside of cancer care as well [41]. In this light and in view
of increasing government policy focus on patient
involvement in care [13], there is a need for more discus-
sion with regulators around the types of policies and
guidelines for the administration and use of QoL tools [14],
the place of QoL in value based assessments and on the
health economics of QoL, and how to most effectively
communicate QoL assessment results from clinical trials to
the those making prescription decisions, both regulators
and clinicians. In addition, the literature suggests that QoL
measures might be most useful for care where they come
with specific recommendations for changing care or deci-
sion guidelines to help clinicians translate the scores [5,
32].
There are some limitations to consider regarding the
evidence included in the systematic review, and in the
review itself. First despite the number of RCTs identified in
the systematic review, the majority of included studies
were at high risk of bias due to a lack of blinding and/or
high drop-outs rates with ‘‘as-treated’’ analysis done. In
addition, a number of studies had small sample sizes and
were conducted among high functioning individuals. Given
these methodological limitations, the reliability of some of
the results is uncertain. In addition, there were method-
ological differences between studies in the definition and
Table 4 Factors influencing the use of QoL tools in cancer care, identified in interviews
Facilitators Challenges
System-level factors A formal requirement for use in trials can influence care of
patients participating in trials and patients in settings where
trials take place
Availability of human resources (e.g. trained nurses and
doctors to administer and interpret findings)
Value placed on patient perspectives and patient engagement
by the health system
Although rare, the presence of guidelines on tool usea
A general lack of policy and guidelines for the use of
QoL instruments in cancer care contexts
A need for training of health professionals, confounded
by health system resource constraints and time demands
Challenges to effectively communicating QoL findings
from clinical trials to the point of prescription
A lack of insights on the place of QoL assessment
findings in valuations of drugs
Tool-related factors A relatively simple design is important in a care context (with
simplicity being relatively less important in trial contexts
where the capacity and resources to cope with more
detailed instruments is better established)
Ability of questions to address aspects of QoL that are
meaningful to the patient and the clinician (this are not
mutually exclusive but not always the same in priority)
Scope for remote administration (e.g. iPads, telephone
administration) but requires reliable devices, software and
training
No ‘‘gold standard’’: perceptions of overly complex or
overly simple designs and the associated need for some
standardisation in trials but sufficient tailoring for care
contexts (across patient profiles and cancer types and
stages)
Cultural specificities associated with HRQoL and
implications on the nature of questions that need to be
asked
Having patients complete (and staff process) different





Follow-up on findings with patient/carer as key for public
acceptability of tools and their take-up
A general lack of awareness about the diversity of
available tools and how to access and engage with
them, among cancer patients
Scope for proxy-reporting (but not without trade-offs) when
patients are unable to complete questionnaires directly (e.g.
due to issues such as cognitive decline)
Shifting patient expectations of HR QoL during the
course of disease
Patient versus proxy views can be different
a For example, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have a guideline on the use of
the distress thermometer
34 INT03.
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scope of QoL domains measured, assessment tools used,
clinical settings and outcomes reported, making compar-
ison of results between studies difficult. These method-
ological limitations have been widely acknowledged
elsewhere [1, 5, 42, 43], suggesting that trials need to be
further standardised to allow a more robust analysis of the
use of QoL tools in clinical practice. However, the need for
standardisation in trials needs to weighed against a degree
of customisation in care to ensure patient-centred instru-
ments that facilitate patient-centred care [13, 14, 40].
Regarding the systematic review, we took a number of
steps to minimise selection and reviewer biases, but it is
possible that some relevant studies may have been missed,
such as those published in non-English languages. More-
over, our review inclusion/exclusion criteria were very
focused, and there are likely other outcomes/complemen-
tary reviews that need to be considered when evaluating
impact.
We interviewed a limited number of key informants and
aimed to cover a diversity of experiences across sectors,
professions and countries. We drew on individuals identi-
fied through the literature and a snow-balling approach.
Whereas we found a high level of agreement across
interviewees’ accounts, both within and between countries,
it is possible that a future research agenda could increase
the scale and scope of countries and experts covered and
that an effort to consider experiences across diverse cancer
contexts (types of disease and stages of disease) would
offer further learning. For example, despite repeated
efforts, the research team was not successful in recruiting a
key informant from the USA, at the time of this study. This
could have offered important additional insights given the
number of tools identified in this study from the USA. We
aimed to mitigate this limitation through consultation with
representatives at the IBTA World Summit, which included
participants from diverse country contexts, including the
USA. Evidence from our systematic literature review,
selected key informant interviews and wider consultation at
a conference of selected attendees, suggest that HRQoL
tools may improve patient–physician communication, and
have the potential to improve care, but that they are not
widely used in clinical practice. There is a need for further
research and stakeholder engagement on how HRQoL tools
can achieve impact across different cancer and patient
group contexts, in real-world settings. There is also a need
for policy, health professional, research and patient com-
munities to strengthen information exchange, support
awareness raising, maintain a debate and provide training
on tool design, use and interpretation.
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Box 1 Specific examples of how QoL assessment tools are being used in the care of cancer patients, including brain cancer as reported in interviews
Tool used in care delivery, as
reported in interviews
Use
Distress Thermometer Used in the care of patients with a variety of cancers including brain cancer, in some neuro-oncology
settings in the Netherlands. Dutch guidelines for psychosocial care of cancer patients recommend
the use of QoL measures, and, as one interviewee noted, although it ‘‘… is not a real QoL
instrument… it makes it possible to discuss QoL with patients… and can help to detect complaints
and issues’’. (INT04). This in turn was seen to facilitate more appropriate referral pathways
Distress Assessment and Response
Tool (DART)
Mandated by the provincial government of Ontario as a general cancer QoL measure for assessing
all patients in cancer centres in Ontario, Canada. It is administered each time a patient visits the
clinic (unless they are undergoing daily radiation treatment). The data are used by clinicians who
scan the results before meeting patients and can ask patients specific questions that warrant
attention in follow-up
Psychological Screen for Cancer
(PSCAN)
Used by the British Columbia Cancer Agency in Canada, as part of its Patient and Family
Counselling Services Initiative, as it covers issues they feel counselling can help with. It is
currently administered to all patients at their first visit, and they are trialling using it repeatedly
during a patient’s care
Barthel Index Used in clinical practice in some settings in Spain to gather information on the status of a brain
cancer patient, in terms of performance in activities of daily living
The tools listed are examples provided by interviewees. There was reported to be a debate as to what is considered an official QoL assessment
tool. As such, the tools listed might not be recognised as a formal QoL assessment tool by some professions, and their use may be limited to
specific settings
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